Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation
- PMID: 9620500
- DOI: 10.1097/00000539-199806000-00008
Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation
Abstract
We conducted a prospective, randomized study to determine the efficacy of conjugated estrogen in reducing blood product transfusion during orthotopic liver transplantation (OLT). Patients undergoing OLT were included in the study. Only those having a reaction time of more than 30 mm or 15 min (19 -28 mm) on computed thromboelastography (CTEG) at the beginning of surgery were enrolled in the study. Patients were randomized to receive either conjugated estrogen (CE) or placebo. Every patient received a first dose of CE (100 mg i.v.) (20 mL) or placebo (20 mL of isotonic sodium chloride solution) at the beginning of the procedure and a second dose of CE (100 mg i.v.) or 20 mL of placebo (20 mL of isotonic sodium chloride solution) just after reperfusion of the new graft. The two groups were similar in age, weight, requirement for veno-veno bypass, time on veno-veno bypass, CTEG measurement, and preoperative hemoglobin and platelet values. Blood products were given in relation to hematocrit and coagulation (CTEG) variables, which were measured every hour during the surgery. The amount of transfused blood products did not differ in terms of units of cryoprecipitate, but the intraoperative requirements for red blood cells (6 +/- 3 vs 9 +/- 6 U; P = 0.05), platelets (12 +/- 8 U vs 18 +/- 10 U; P = 0.05) and fresh-frozen plasma (3 +/- 3 U vs 6 +/- 4 U; P = 0.001) was significantly less in the estrogen group than in the control group. We conclude that CE is associated with a significant decrease in use of fresh-frozen plasma, platelets, and red blood cells during OLT.
Implications: In this study, we prospectively investigated whether i.v. conjugated estrogen could decrease blood product transfusion during orthotopic liver transplantation. Conjugated estrogen-treated patients received less fresh-frozen plasma, red blood cells, and platelets. In this population of patients, conjugated estrogen can be a useful addition in coagulation management during orthotopic liver transplantation.
Comment in
-
Transfusion requirements in orthotopic liver transplantation.Anesth Analg. 1999 Mar;88(3):692. doi: 10.1097/00000539-199903000-00046. Anesth Analg. 1999. PMID: 10072032 No abstract available.
Similar articles
-
Effectiveness of conjugated estrogen in orthotopic liver transplantation.South Med J. 1998 Apr;91(4):365-8. doi: 10.1097/00007611-199804000-00010. South Med J. 1998. PMID: 9563429
-
Rotational Thromboelastometry or Conventional Coagulation Tests in Liver Transplantation: Comparing Blood Loss, Transfusions, and Cost.Ann Hepatol. 2017 November-December,;16(6):916-923. doi: 10.5604/01.3001.0010.5283. Ann Hepatol. 2017. PMID: 29055918
-
Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial.J Thorac Cardiovasc Surg. 2013 Mar;145(3 Suppl):S178-85. doi: 10.1016/j.jtcvs.2012.12.083. J Thorac Cardiovasc Surg. 2013. PMID: 23410777 Clinical Trial.
-
Roles of thrombelastography and thromboelastometry for patient blood management in cardiac surgery.Transfus Med Rev. 2013 Oct;27(4):213-20. doi: 10.1016/j.tmrv.2013.08.004. Epub 2013 Sep 26. Transfus Med Rev. 2013. PMID: 24075802 Review.
-
Hemostasis in liver transplantation: Pathophysiology, monitoring, and treatment.World J Gastroenterol. 2016 Jan 28;22(4):1541-50. doi: 10.3748/wjg.v22.i4.1541. World J Gastroenterol. 2016. PMID: 26819521 Free PMC article. Review.
Cited by
-
Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: a systematic review.Rev Bras Cir Cardiovasc. 2014 Oct-Dec;29(4):606-21. doi: 10.5935/1678-9741.20140114. Rev Bras Cir Cardiovasc. 2014. PMID: 25714216 Free PMC article.
-
Methods to decrease blood loss and transfusion requirements for liver transplantation.Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD009052. doi: 10.1002/14651858.CD009052.pub2. Cochrane Database Syst Rev. 2011. PMID: 22161443 Free PMC article.
-
Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery.Drugs. 2002;62(15):2193-211. doi: 10.2165/00003495-200262150-00003. Drugs. 2002. PMID: 12381219 Review.
-
Risk Factors Associated with Reoperation for Bleeding following Liver Transplantation.HPB Surg. 2014;2014:816246. doi: 10.1155/2014/816246. Epub 2014 Nov 20. HPB Surg. 2014. PMID: 25505820 Free PMC article.
-
A benefit-risk review of systemic haemostatic agents: part 1: in major surgery.Drug Saf. 2008;31(3):217-30. doi: 10.2165/00002018-200831030-00003. Drug Saf. 2008. PMID: 18302446 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical